Research Development Services office will continue to actively support the Mason community during the time of reduced campus operations. All staff will be working remotely but continue to provide support to faculty, students and staff in managing the Limited Submission Opportunities and internal application reviews as needed; creating training materials for proposal development; providing proposal management and support for large, complex, multidisciplinary proposals; and offering guidance on seeking funding opportunities through the Sponsored Programs Innovation Network (SPIN). All staff will be working remotely. Please feel free to contact Rebekah Hersch, Assistant Vice President, Research Development (email@example.com) if you have questions. For information about the Limited Submission Opportunities, please contact Sheila Davis (firstname.lastname@example.org).
COVID-19 Datasets and Analytic Resources
- Academic Data Science Alliance is curating and updating a list of open datasets and analytic resources on their website. You can find more information on available datasets and resources here: www.academicdatascience.org/covid
- NLM released the COVID-19 Open Research Dataset (CORD-19) of scholarly literature related to COVID-19, SARS-CoV-2, and the Coronavirus group. To make full of this dataset, the White House Office of Science and Technology Policy (OSTP) has issued a call for tech and AI experts to develop new text and data mining techniques that can be used to help the science community answer high-priority scientific questions related to COVID-19.
- The Pittsburgh Supercomputing Center (PSC) is currently hosting the COVID-19 database for the National Genomics Data Center of the Chinese People’s Republic. By providing ready access to this important dataset, they hope to enable researchers to better understand the COVID-19 virus. https://www.psc.edu/bridges-for-covid-19-research
- The scientific platform Galaxy at the Pennsylvania State University has developed an open source set of computer tools for helping scientists studying the COVID-19 virus obtain transparent and reproducible results. For more information see https://covid19.galaxyproject.org/
- NVIDIA is providing a software called Parabricks free for 90 days to organizations doing research on COVID19. The Argo cluster meets the minimum requirements. Please contact Jayshree Sarma (email@example.com) if you are interested in using the software. https://blogs.nvidia.com/blog/2020/03/19/coronavirus-research-parabricks/?ncid=em-news-57155#cid=ix01_em-news_en-us . Parabricks software (https://www.developer.nvidia.com/nvidia-parabricks) is used for genome sequencing and uses GPU (Graphical Processing Unit) for speeding up the analysis.
- Georgetown COVID-19 Open Research Dataset: https://pages.semanticscholar.org/coronavirus-research
- The COVID-19 High Performance Computing Consortium: Researchers interested in applying for COVID-19 research allocation on the XSEDE supercomputers can apply here: https://campuschampions.web.illinois.edu
- Facebook Enabling COVID-19 Research with New Data Sets. To support ongoing COVID-19 research and to help inform public health decisions, CMU and UMD made the aggregated data from these surveys publicly available. Learn more here: https://research.fb.com/blog/2020/05/expanding-support-for-covid-19-research-through-the-symptom-surveys/
- The National Science Foundation has awarded the University of Virginia a $1.2 million expansion of a grant to develop a secure, high-performance computing system for research, with the new funds supporting nationwide use of the system for COVID-19 research. Learn more here: https://www.hpcwire.com/off-the-wire/uva-leads-nationwide-project-to-protect-health-data-for-covid-19-research/ (Additional funding is available to all COVID-19 research at Mason)
COVID-19 Funding Opportunities
The following table lists funding opportunities relating to the COVID-19 virus. We will continue to update this list as new opportunities become available. If you would like to add opportunities to this list please feel free to contact Heather Arold at firstname.lastname@example.org.
|Program Title||Sponsor||Deadline||Funding Amount||Brief Synopsis|
|Fast Grants||Emergent Ventures||None Posted||$500,000||Emergent Ventures invites applications from scientists at academic institutions currently working on a COVID-19 related project and in need of funding. Fast Grants will range from $10,000 to $500,000.|
|RFA-FD-22-003 -- Innovation Award: COVID-19 and Health Equity (U01) Clinical Trials Optional||Food and Drug Administration/DHHS||5-Oct-21||Not Available||The purpose of this funding opportunity announcement (FOA) is to fund innovative research that will strengthen and advance COVID-19 health equity research. Proposals that focus on advancing racial and ethnic minority participation in COVID-19/COVID-19 variant clinical trials and/or contribute to informing the continued evaluation of the safety and efficacy of FDA approved products (therapeutics, diagnostics, and vaccines) or products subject to EUAs/EUA expansion for the treatment, prevention, or diagnosis of COVID-19. Proposals that support the evaluation of outcomes by demographic data including, but not limited to, ethnicity, race, age, disability, and geography. Proposals that support COVID-19 research to understand diverse patient perspectives, preferences, and unmet needs|
|Urgent Award: Social, Behavioral, and Economic Research on COVID-19 Consortium (U01 Clinical Trial Not Allowed)||National Institutes of Health/DHHS||8-Nov-21||Not Available||The purpose of this FOA is to advance research on the impact of SARS-CoV-2 and associated mitigation efforts on individual, family, and community behavior and on how subsequent economic disruption affects health-related outcomes, with close attention to underserved and vulnerable populations.|
|Emergency Competitive Revision to Existing NIG Awards (Emergency Supplement - Clinical Trial Optional)Emergency Competitive Revision to Existing NIG Awards (Emergency Supplement - Clinical Trial Optional)||National Institutes of Health/DHHS||None Posted||None Posted||The National Institutes of Health (NIH) hereby notify the applicant community that funds may be available for applications based on a presidentially declared disaster under the Stafford Act, a public health emergency declared by the Secretary, HHS, or other local, regional or national disaster. Applications in response to Emergency Notices of Special Interest (NOSIs) will be routed directly to the NIH awarding component signed on to the Emergency NOSI.|
|Ecology and Evolution of Infectious Diseases (EEID)||National Science Foundation||11/17/2021||Not Available||The multi-agency Ecology and Evolution of Infectious Diseases program supports research on the ecological, evolutionary, and social drivers that influence the transmission dynamics of infectious diseases. The central theme of submitted projects must be the quantitative or computational understanding of pathogen transmission dynamics. The intent is discovery of principles of infectious disease transmission and testing mathematical or computational models that elucidate infectious disease systems. Projects should be broad, interdisciplinary efforts that go beyond the scope of typical studies. They should focus on the determinants and interactions of transmission among any host species, including but not limited to humans, non-human animals, and/or plants. This includes, for example, the spread of pathogens; the influence of environmental factors such as climate; the population dynamics and genetics of reservoir species or hosts; the feedback between ecological transmission and evolutionary dynamics; and the cultural, social, behavioral, and economic dimensions of pathogen transmission. Research may be on zoonotic, environmentally-borne, vector-borne, or enteric pathogens of either terrestrial or aquatic systems and organisms, including diseases of animals and plants, at any scale from specific pathogens to inclusive environmental systems. Proposals for research on disease systems of public health concern to developing countries are strongly encouraged, as are disease systems of concern in agricultural systems. Investigators are encouraged to develop the appropriate multidisciplinary team, including for example, anthropologists, modelers, ecologists, bioinformaticians, genomics researchers, social scientists, economists, oceanographers, mathematical scientists, epidemiologists, evolutionary biologists, entomologists, parasitologists, microbiologists, bacteriologists, virologists, pathologists or veterinarians, with the goal of integrating knowledge across disciplines to enhance our ability to predict and control infectious diseases.|
|Mail-in Protein-to-Structure Services to Support Structural Biology Research Related to COVID-19 at the EMBL Grenoble HTX Lab and the Joint ESRF-EMBL MX Beamlines||European Synchrotron Radiation Facility||None Posted||Not Available||The ESRF-EMBL Joint Structural Biology Group (JSBG) invite COVID-19 related proposals that can benefit from the seamless integration of the EMBL High throughput Crystallization Facility (HTX Lab) with the highly automated JSBG MX beamlines at the ESRF. The pipeline starts with mail-in samples and integrates crystallization screening, crystal optimization, ligand soaking if required and eventually fragment screening with libraries of up to 1200 fragments. Crystals obtained will be automatically harvested and passed to the ESRF for automated X-ray data collection, with real-time access to experimental results and parameters. This pipeline is uniquely suited to support of structural biology projects in conditions of confinement and restricted access to labs. The HTX lab is already accepting crystallization projects on COVID-19 related research and three ESRF beamlines (MASSIF-1 (ID30A-1), ID30B and ID23-2) will become operational after 11 May 2020.|
|Notice Announcing the Availability of Common Data Elements for Research Related to the Public Health Emergency caused by Coronavirus Disease 2019 (COVID-19)||National Institute of Mental Health/NIH||None Posted||Not Available||The purpose of this Notice is to extend the data-harmonization effort at the National Institute of Mental Health (NIMH) announced in NOT-MH-15-009 to research protocols pertaining to the public health emergency caused by COVID-19, the disease caused by SARS-CoC-2).|
|Pioneering Ideas: Exploring the Future to Build a Culture of Health||Johnson (Robert Wood) Foundation||None Posted||Not Available||The Pioneer team seeks to anticipate the future, and support unconventional approaches and breakthrough ideas that can help lead the way to a future where everyone in the United States can live their healthiest life possible. The Pioneering Ideas: Exploring the Future to Build a Culture of Health call for proposals (CFP) seeks applications from visionary thinkers across the nation who are doing cutting-edge work to advance health equity.|
|COVID-19 HPC Consortium||Extreme Science and Engineering Discovery Environment (XSEDE)||None Posted||Not Available||The COVID-19 HPC Consortium encompasses computing capabilities from some of the most powerful and advanced computers in the world. XSEDE hopes to empower researchers around the world to accelerate understanding of the COVID-19 virus and the development of treatments and vaccines to help address infections. Consortium members manage a range of computing capabilities that span from small clusters to some of the very largest supercomputers in the world.|
|Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions for Modeling Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2||National Institute of General Medical Sciences/NIH/DHHS||15-Dec-2021||Not Available||NIGMS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for modeling research on SARS-CoV-2 and Coronavirus Disease 2019 (COVID-19).|
|Notice of Special Interest (NOSI): Aging-Relevant Behavioral and Social Research on Cornonavirus Disease 2019 (COVID-19)||National Institute on Aging/NIH/DHHS||None Posted||Not Available||NIA is issuing this Notice of Special Interest (NOSI) to highlight the continuing need for behavioral, psychological, social, and economic research on SARS-CoV-2 and coronavirus disease 2019 (COVID-19). There is a need for ongoing research on the longer-term effects of COVID-19 on the health and well-being of those infected, those caring for the sick, and many others whose lives were disrupted by the pandemic and its associated mitigation and prevention strategies. Beyond effects on individuals, this pandemic has brought about unprecedented social and economic disruption that is expected to have long-term and profound effects on the health of the population. These effects will likely be particularly acute for NIH-designated health disparity populations, and other COVID-19 vulnerable groups including older adults, who have experienced higher rates of COVID-19 infection, who in some cases rely on the efforts of paid and unpaid care partners, and who may have additional barriers to accessing the medical system itself. Further, middle-aged and older frontline healthcare and essential workers and their families face unique risks of exposure to both infection and other health-related outcomes by virtue of their employment.|
|Notice of Special Interest (NOSI): Limited Competition for Emergency Competitive Revisions for Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 from Skin and the Oral Cavity for Rapid Acceleration of Diagnostics Radical (RADx-rad)||National Institutes of Health/DHHS||None Posted||$500,000||NIH is issuing this NOSI in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). This emergency NOSI from the National Institutes of Health (NIH) provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. The goal of the RADx-rad initiative is to encourage the development of novel, non-traditional approaches to identify the current SARS-CoV-2 virus or other markers of the COVID-19 disease that can be used in future outbreaks of COVID-19 and that could be applicable to other, as yet unknown, viruses. Specifically, the goal of this NOSI is to advance early stage biosensing technologies intended for the detection of volatile organic compounds (VOCs) emanating from skin and/or multiple (i.e., biologic, chemical and physical) biosignatures captured from the oral cavity in COVID-19. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.|
|Notice of Special Interest (NOSI): Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus and the Behavioral and Social Sciences||National Institutes of Health/DHHS||None Posted||Not Available||This Notice of Special Interest (NOSI) highlights the urgent need for social, behavioral, economic, health communication, and epidemiologic research relevant to the 2019 Novel Coronavirus (SARS-CoV-2) and COVID-19. This NOSI encourages urgent competitive supplements and administrative supplements to existing longitudinal studies that address key social and behavioral questions related to the COVID-19 pandemic, including adherence to and transmission mitigation from various containment and mitigation efforts; social, behavioral, and economic impacts from these containment and mitigation efforts; and downstream health impacts resulting from these social, behavioral, and economic impacts, including differences in risk and resiliency based on gender, race and ethnicity, socioeconomic status, and other social determinants of health.|
|Notice of Special Interest (NOSI): Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19)||National Center for Advancing Translational Sciences/NIH/DHHS||None Posted||Not Available||NCATS is issuing this Notice of Special Interest to highlight the urgent need for research on the 2019 novel coronavirus and the disease it causes, i.e. "coronavirus disease 2019" (COVID-19). NCATS is particularly interested in projects that repurpose existing drugs or biologics (existing therapeutics) that have already begun or completed a Phase I clinical trial.|
|COVID-19 Medical Countermeasures Consultant Support||Department of Defense||None Posted||Not Available||1. Scope: The current COVID-19 pandemic demands immediate action in developing life-saving Medical Countermeasures (MCM), which encompass technical efforts from early development through their Food and Drug Administration (FDA) approval. This document provides a summary of the Department of Defense (DOD) and Operation Warp Speed (OWS) major integrated efforts that include but are not limited to leveraging the use of Senior Subject Matter Experts (SMEs) consultants with recognized expertise in MCM development in a variety of disciplines, such as: diagnostics, vaccines, polyclonal antibodies (pAbs), and large and small molecule drug development efforts from early development through FDA approval and Post Licensure related efforts. The Government will draw upon consultant expertise of SMEs to support the Joint Program Executive Office, Chemical, Biological, Radiological & Nuclear Defense (JPEO-CBRND) mission through the development of MCM in the three major MCM domains: Diagnostics, Prevention, and Treatment for COVID-19. SMEs will include senior pharmaceutical technical experts to ensure the JPEO can accomplish the mission to deliver MCMs to DoD personnel and to the nation. Nested within these major integrated MCM development efforts are numerous technical challenges to clinical, non-clinical, and manufacturing processes, up to full scale production to obtain FDA approval. The consultant pharmaceutical SMEs will augment DOD MCM developers and contribute to analysis, assessment, design, and evaluation of alternative approaches to achieve the rapid development of MCMs against COVID-19. They will increase efficiency and effectiveness, reduce the risks, and shorten the schedule of delivering MCMs to protect the U.S. military, coalition forces, and the nation from the current COVID-19 pandemic. 2. The Government has determined that the need to accelerate COVID-19 development is of such an unusual and compelling urgency (FAR.6.302-2) that the Government has pursued a sole source procurement for the consultant services described above. The contract will have a Base Period of six (6) months duration, with the option to extend services in accordance with FAR 52.217-9 for a further six months.|
|Competitive Fund for Peace and Recovery||Innovations for Poverty Action||None Posted||Not Available||The Peace & Recovery (P&R) Program supports field experiments and related research on reducing violence and fragility, promoting peace, and preventing, managing, and recovering from crises. Currently, the sponsor is accepting Research Proposals for COVID-19 Response and Off-Cycle Research Proposals for Research on Homicide Reduction in Latin America and the Caribbean.|
|Small Grants Program in Behavioral Economics||Sage (Russell) Foundation||None Posted||$8,500||The Russell Sage Behavioral Economics Roundtable supports a small grants research program to support high quality research in behavioral economics and to encourage young investigators (Ph.D. students and recent graduates) to enter this developing field.|
|COVID-19 Vaccines: Accelerating Vaccine Development and Global Manufacturing Capacity to Stop the Pandemic||Coalition for Epidemic Preparedness Innovations (CEPI)||None Posted||Not Available||The objective of this Call for Proposals is to support the rapid development of vaccines against COVID-19 with a goal of achieving licensure/emergency authorisation in 12-18 months or less and to ensure the availability of sufficient doses for wide-spread global deployment as soon as possible in 2021.|
|SARS-CoV-2 (COVID-19) Program Activities||Assistant Secretary of Health/DHHS OS-PAW||None Posted||None Posted||The Office of the Assistant Secretary for Health (OASH) has established the Laboratory and Diagnostics Working Group (LDWG) seeking submissions to a Broad Agency Announcement (BAA) “to prevent, prepare for, and respond to coronavirus, domestically or internationally, for necessary expenses to research, develop, validate, manufacture, purchase, administer, and expand capacity for COVID–19 tests to effectively monitor and suppress COVID–19…” (Paycheck Protection Program and Healthcare Enhancement Act (P.L. 116-139)). OASH/LDWG seeks proposals for projects that will further enable the coordination and development of testing and associated products that meet the current and future needs, and the effective transition of technology into broad use without impediments. The primary areas of focus should specifically include (1) Scaling and Networking of Technologies, and (2) Testing Demonstrations & Technical Assistance. Specifically, OASH is interested in submissions that will substantially increase our testing capacity and quality in the near term, and do not fall within the scope of other HHS programs.|
|6640--COVID-19 Cephieid Equipment COVID-19 Testing Emergency Requirement||Department of Veterans Affairs||None Posted||Not Available||Description of Supplies or Services: The estimated value of the proposed action is $ 323,040.00. Cepheid has developed an automated molecular test for the qualitative detection of SARS-CoV2, the virus that causes COVID-19 on the GeneXpert Systems. Cepheid is the only authorized US manufacturer and distributor of this instrumentation for polymerase chain reaction (PCR) molecular technology. These instruments are also compatible and will integrate with systems currently installed in the facilities, streamlining the validation and implementation process.|
|Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)||National Institutes of Health/DHHS||None Posted||Not Available||National Institutes of Health (NIH) hereby notify Program Directors/Principal Investigators (PD(s)/PI(s)) holding specific types of NIH research grants listed in the full Funding Opportunity Announcement (FOA) that funds may be available for administrative supplements to meet increased costs that are within the scope of the approved award, but were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for administrative supplements are considered prior approval requests (as described in Section 188.8.131.52 of the NIH Grants Policy Statement) and will be routed directly to the Grants Management Officer of the parent award. Although requests for administrative supplements may be submitted through this FOA, there is no guarantee that funds are available from the awarding IC or for any specific grant. All applicants are encouraged to discuss potential requests with the awarding IC. Additionally, prior to submission, applicants must review the awarding IC's web site to ensure they meet the IC's requirements.|
|Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)||National Institutes for Health/DHHS||None Posted||Not Available||The National Institutes of Health (NIH) hereby notify the applicant community that funds may be available for applications based on a presidentially declared disaster under the Stafford Act, a public health emergency declared by the Secretary, HHS, or other local, regional or national disaster. Applications in response to Emergency Notices of Special Interest (NOSIs) will be routed directly to the NIH awarding component signed on to the Emergency NOSI.|
|Covid-19 Scientific Research||European Synchrotron Radiation Facility||None Posted||Not Available||The ESRF is ready to provide access to its facilities for Covid-19 related research projects. This exceptional access will be granted with the aim to contribute to the international scientific effort to overcome the covid-19 pandemic.|
|Grants Program||COVID-19 Early Treatment Fund (CETF)||None Posted||Not Available||CETF will be funding initiatives that focus on treating outpatients with COVID-19 to prevent hospitalization. Grant recipients are required to share what they learn with others.|
|Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)||National Institutes of Health/DHSS||None Posted||Not Available||The National Institutes of Health (NIH) hereby notify Principal Investigators holding specific types of NIH research grants, listed in the full Funding Opportunity Announcement (FOA) that funds may be available for competitive revisions to meet immediate needs to help address a specific public health crisis in a timely manner, but that were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for Urgent Competitive Revisions will be routed directly to the NIH awarding component listed on the NoA of the most recent parent award. Only applications submitted in response to an Urgent Guide Notice published by an IC will be allowed to apply to this FOA.|
|2020 COVID-19 FlexGrants||West Coast Consortium for Technology & Innovation in Pediatrics||None Posted||$15,000||The West Coast Consortium for Technology & Innovation in Pediatrics (CTIP) is announcing a limited grant opportunity to support pediatric medical device innovators who are able to use their technology to aid in the current COVID-19 pandemic. Companies will be awarded grants up to $15,000 to support activities that apply or adapt their existing medical device to help manage the health impacts of the crisis on children. Medical devices with adult indications that are expanding or wish to expand their clinical indication to pediatrics are welcome to apply.|
|ICESCO Prize for Fighting Against Coronavirus||Islamic World Education, Scientific, and Cultural Organization||None Posted||$200,000||In response to the World Health Organization's appeal to the international community to "seize every opportunity to curb, contain, combat, and delay the spread of the virus, and mitigate its impact", the Islamic World Education, Scientific, and Cultural Organization (ICESCO) announces its Prize for Fighting Novel Coronavirus (COVID-19). The amount of the prize is US$200,000, including an award medal.|
|COVID-19 Response: A Call for Ideas||COVID-19 Response: A Call for Ideas||None Posted||Not Available||The Mercatus Center, building on its COVID-19 policy brief series, welcomes proposals for policy briefs, working papers, and articles that address the next round of challenges facing the United States and other countries in the response to the pandemic.|
|Access to Platform for Partner COVID-19 Projects||Ginkgo Bioworks||None Posted||Not Available||Ginkgo Bioworks has committed its platform to supporting research and development efforts for COVID-19, including $25M of free access to its infrastructure.|
|Expedited, Rapid Access Call for COVID-19 Research||Argonne National Laboratory||None Posted||Not Available||Argonne National Laboratory|
|COVID-19 Research Support||Brookhaven National Laboratory||None Posted||Not Available||The Center for Biomolecular Structure team is supporting remote macromolecular crystallography experiments at Beamlines 17-ID-1 (AMX) and 17-ID-2 (FMX) for research projects related to COVID-19.|
|COVID-19 Vaccine Development Award||MMS Holdings Inc.||None Posted||$1,000,000||The sponsor is offering a USD1M award toward the development of a vaccine for COVID-19, also known as the coronavirus. The award is being offered in the form of data and related services to qualified pharmaceutical and clinical research companies supporting the commercial development of a vaccine for approval in the United States and/or other global health authorities.|
|Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R21 Clinical Trial Not Allowed)||Department of Health & Human Services||Rolling Submission||$275,000||The purpose of this Funding Opportunity Announcement (FOA) is to provide an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19).|
|Notice of Information: Contributing to the Global COVD-19 Crisis response by Allowing Some NCI-supported Projects to be Redirected to COVID-19-related Research During the Crisis||National Institutes of Health/DHSS||None Posted||Not Available||The COVID-19 pandemic is a global health crisis that has engaged the attention of researchers who want to be able to contribute their expertise and resources toward a better understanding of the impacts of SARS-CoV-2 infection and COVID-19 disease on cancer patients’ disease progression, response to therapy, care delivery, or survivorship. NCI anticipates that in infrequent cases, NCI-funded investigators will have novel insights and research proposals of immediate relevance to SARS-CoV-2 and COVID-19. In those cases, but only for the duration of the present crisis, NCI would consider requests from its funded grantees and cooperative agreement awardees to engage in limited COVID-19 related research using part of their existing NCI-funded resources.|
|Rapid Access for COVID-19 Research||Rapid Access for COVID-19 Research||None Posted||Not Available||With the continuing spread of the COVID-19 pandemic, the Department of Energy Basic Energy Sciences advanced neutron sources will provide remote rapid access to advanced user facilities to support research into the COVID-19 virus and the search for effective diagnostics and therapies.|
|COVID-19 Response Fund||International Associate for Volunteer Effort||None Posted||$500||The IAVE COVID-19 Response Fund will focus on supporting global volunteer leadership organizations working directly to respond to the pandemic among the most vulnerable populations in order to help build their capacity for response.|
|COVID-19 Rapid Response Fund||Southern Black Girls and Women's Consortium||None Posted||$10,000||The Southern Black Girls and Women's Consortium (SBGWC), a collective of funders, activists and community leaders working to advance the movements for black girls and women in the Deep South, is offering an immediate funding opportunity to support black girls and women and the people who rely on them due to the COVID-19 outbreak.|
|Deuteration & Macromolecular Crystallisation (DEMAX) COVID-19 related Research Projects||European Spallation Source||None Posted||Not Available||The Deuteration & Macromolecular Crystallisation (DEMAX) platform at ESS is offering prioritised access to laboratory services for scientists and researchers working on COVID-19-related research projects.|
|Ferring COVID-19 Investigational Grants||Ferring Pharmaceuticals||None Posted||EUR 25,000||Ferring is interested in funding exploratory, basic, and clinical research grants to collect data and expand knowledge about the effects on SARS-CoV-2 on reproduction, pregnancy, and foetal/neonatal health. The programme will provide a limited number of research grants up to €25,000 for each application.|
|COVID-19 Telehealth Program||Federal Communications Commission||None Posted||$1,000,000||The COVID-19 Telehealth Program will provide $200 million in funding, appropriated by Congress as part of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, to help health care providers provide connected care services to patients at their homes or mobile locations in response to the novel Coronavirus 2019 disease (COVID-19) pandemic.|
|PCORI Funding Opportunity for COVID-19-Related Enhancements to Existing PCORI-Funded Dissemination and Implementation Awards||Patient-Centered Outcomes Research Institute (PCORI)||None Posted||$500,000||PCORI seeks investigator-initiated proposals to address the COVID-19 public health crisis with enhancements to currently funded PCORI Dissemination and Implementation awards. Only PCORI-funded investigators or project leads with active Dissemination and Implementation Award contracts are eligible to submit a proposal in response to this announcement.|
|PCORI Funding Opportunity for COVID-19-Related Enhancements to Existing PCORI-Funded Research Projects||Patient-Centered Outcomes Research Institute (PCORI)||None Posted||$500,000||PCORI is currently seeking Project Lead-initiated proposals to address the COVID-19 public health crisis through enhancements to currently funded PCORI Engagement Awards. Only PCORI-funded project leads with active Engagement Award contracts are eligible to submit a proposal in response to this funding announcement.|
|PCORI Funding Opportunity for COVID-19-Related Enhancements to Existing PCORI-Funded Engagement Awards||Patient-Centered Outcomes Research Institute (PCORI)||None Posted||$150,000||PCORI is currently seeking Project Lead-initiated proposals to address the COVID-19 public health crisis through enhancements to currently funded PCORI Engagement Awards. Only PCORI-funded project leads with active Engagement Award contracts are eligible to submit a proposal in response to this funding announcement.|
|Artist Relief||Americans for the Arts||Not Available||$5,000||Artist Relief will distribute $5,000 grants to artists facing dire financial emergencies due to COVID-19; serve as an ongoing informational resource; and co-launch the COVID-19 Impact Survey for Artists and Creative Workers, designed by Americans for the Arts, to better identify and address the needs of artists.|
|SARS-COV-2 Diagnostics: Performance Data||Foundation for Innovative New Diagnostics (FIND)||Rolling Basis||Not Available||FIND is conducting independent evaluations of SARS-CoV-2 molecular tests and immunoassays. To complement these evaluations, and in partnership with WHO in line with the sponsor's official Collaborating Centre remit, the sponsor is endeavouring to centralize the collection of SARS-CoV-2 diagnostic performance data as a global public good. FIND is working closely with partners including the World Health Organization (WHO) in support of the global effort to combat the COVID-19 pandemic. In this respect, FIND is curating the overall diagnostic pipeline and tracking reported global diagnostic use, as well as conducting independent evaluations of SARS-CoV-2 molecular tests and immunoassays.|
|Priority Access Call for Work on Combating COVID-19||Scherre (Paul) Institute||None Posted||Not Available||The Paul Scherrer Institute (PSI) has opened a "PRIORITY COVID-19 Call” for short proposals and quick peer review to enable rapid access to beamtime. Research proposals shall have the potential to effectively contribute to the understanding of the COVID-19 virus and/or to improve the clinical or public health response and patient care.|
|NIH Small Research Grant Program (Parent R03 Clinical Trail NOT Allowed)||National Institutes of Health/DHSS||On-going (Currently 07-Sept-2020)||$100,000.00||The NIH Small Research Grant Program supports small research projects that can be carried out in a short period of time with limited resources. This program supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s).|
|RFP -- AMENDMENT --- BARDA's Division of Research, Innovation & Ventures (DRIVe) Easy Broad Agency Announcement||Department of Health & Human Services||Continuous||Not Specified||AMENDMENT: 3/9/2020 - Please see Special Instructions 003 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002. Under these Special Instructions, BARDA is adding several new topics under its temporary AOI #4: COVID-19 (renamed from 2019-nCoV) as part of its EZ-BAA (BAA-20-100-SOL-0002). AMENDMENT: 3/18/2020 - Please see Special Instructions 004 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002.|
|Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)||National Institutes of Health (multiple ICs)||Varies by IC||Application budgets are not limited but need to reflect the actual needs of the proposed project.||The National Institutes of Health (NIH) hereby notify the applicant community that funds may be available for applications based on a presidentially declared disaster under the Stafford Act, a public health emergency declared by the Secretary, HHS, or other local, regional or national disaster. Applications in response to Emergency Notices of Special Interest (NOSIs) will be routed directly to the NIH awarding component signed on to the Emergency NOSI.
Only applications submitted in response to an Emergency NOSI published by an IC will be allowed to apply to this FOA.
|Dear Colleague Letter: Request for SBIR/STTR Phase I Proposals Addressing COVID-19 (NSF 20-065)||National Science Foundation||Four Submission Windows:|
3/6/ 2020 6/4/ 2020
6/5/2020 9/3/ 2020
|See SBIR/STTR Guidelines||The Division of Innovation and Industrial Partnerships (IIP) of the Engineering Directorate invites US-based small businesses to submit Phase I proposals focused on the development and deployment of new technologies, products, processes, and services with the potential to positively impact the nations and worlds ability to respond to the COVID-19 crisis. Areas of research that might be considered include, but are not limited to: artificial intelligence, digital health, diagnostics, distributed ledger, environmental technologies, medical devices, pharmaceutical technologies, disinfection and sterilization, and filtration and separations. Interested proposers are invited to submit to the NSF Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Phase I Program. All active NSF SBIR/STTR awardees, and other interested US-based small businesses are eligible to submit a Phase I proposal. Please reference the NSF SBIR and STTR Phase I solicitations for more details regarding eligibility.|
|Coronavirus Local Response Initiative||Bloomberg Philanthropies||Continuous Submission||Not Specified||Bloomberg Philanthropies will work with partners to identify the needs and lessons learned from cities experiencing the outbreak in real time that can be shared with additional cities eager to get ahead of the virus spread. Relying on public health expertise from the Johns Hopkins Bloomberg School of Public Health, the network will provide mayors with the most up-to-date information on the virus from the Centers for Disease Control and help them understand and act on the most relevant and accurate information available.
The program is open to all cities in the United States and will accommodate as many participants as possible. (tld)
|Dear Colleague Letter--Coronavirus Disease 2019 (COVID-19)||Department of Energy||Continuous Submission||Not Specified||Through its user facilities, computational power, and enabling infrastructure, DOE has unique capabilities that the scientific community may leverage for the COVID-19 response and recovery. DOE does not provide medical and clinical work; instead, the Department's mission complements the efforts of the National Institutes of Health, the Department of Defense, and other Federal partners by helping to understand the scientific phenomena contributing to COVID-19, from the structure of the SARS-CoV-2 virus, which causes the disease, to models that can mimic its spread. DOE supports significant biologically focused facilities and resources, including the Joint Genome Institute (JGI), National Microbiome Data Collaborative (NMDC), Environmental Molecular Science Laboratory (EMSL), and DOE Systems Biology Knowledgebase (KBase). These and other DOE resources may be used for many studies. The Department encourages submission of scientific questions that underpin COVID-19 response and that the research community may answer using DOE user facilities, computational resources, and enabling infrastructure. The Department is acting rapidly to leverage, and when appropriate provide prioritized access to, the full range of DOE user facilities and other facilities available at national laboratories to support the national and international effort to address COVID-19.|
|Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)||National Institutes of Health/DHHS||Varies by IC||Application budgets are not limited but need to reflect the actual needs of the proposed project.||The National Institutes of Health (NIH) hereby notify Principal Investigators holding specific types of NIH research grants, listed in the full Funding Opportunity Announcement (FOA) that funds may be available for competitive revisions to meet immediate needs to help address a specific public health crisis in a timely manner, but that were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for Urgent Competitive Revisions will be routed directly to the NIH awarding component listed on the NoA of the most recent parent award.
Only applications submitted in response to an Urgent Guide Notice published by an IC will be allowed to apply to this FOA. Individual(s) must hold an active grant or cooperative agreement, and the research proposed in the supplement must be accomplished within the competitive segment of the active award. Individuals are encouraged to work with their organizations to develop applications for support
|Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)||National Institutes of Health/DHHS||Varies by IC||Application budgets are limited to no more than the amount of the current parent award, and must reflect the actual needs of the proposed project.|| The National Institutes of Health (NIH) hereby notify Program Directors/Principal Investigators (PD(s)/PI(s)) holding specific types of NIH research grants listed in the full Funding Opportunity Announcement (FOA) that funds may be available for administrative supplements to meet increased costs that are within the scope of the approved award, but were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for administrative supplements are considered prior approval requests (as described in Section 184.108.40.206 of the NIH Grants Policy Statement; https://grants.nih.gov/grants/policy/nihgps/HTML5/section_8/8.1_changes_in_project_and_budget.htm#Need) and will be routed directly to the Grants Management Officer of the parent award.
Although requests for administrative supplements may be submitted through this FOA, there is no guarantee that funds are available from the awarding IC or for any specific grant. All applicants are encouraged to discuss potential requests with the awarding IC. Additionally, prior to submission, applicants must review the awarding IC's web site to ensure they meet the IC's requirements. A list of those web sites is available at https://grants.nih.gov/grants/guide/admin_supp/index.htm.
|Dear Colleague Letter on the Coronavirus Disease 2019(COVID-19); NSF 20-052||National Science Foundation||Varies||Varies||In light of the emergence and spread of the coronavirus disease 2019 (COVID-19) in the United States and abroad, the National Science Foundation (NSF) is accepting proposals to conduct non-medical, non-clinical-care research that can be used immediately to explore how to model and understand the spread of COVID-19, to inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge.
NSF encourages the research community to respond to this challenge through existing funding opportunities. In addition, we invite researchers to use the Rapid Response Research (RAPID) funding mechanism, which allows NSF to receive and review proposals having a severe urgency with regard to availability of or access to data, facilities or specialized equipment as well as quick-response research on natural or anthropogenic disasters and similar unanticipated events. Requests for RAPID proposals may be for up to $200K and up to one year in duration. Well-justified proposals that exceed these limits may be entertained. All questions should be directed either to a program officer managing an NSF program with which the research would be aligned or to email@example.com.
|Dear Colleague Letter: Provisioning Advanced Cyberinfrastructure to Further Research on the Coronavirus Disease 2019 (COVID-19); NSF 20-055||National Science Foundation||Varies||Varies||This Dear Colleague Letter (DCL) complements a separate National Science Foundation (NSF) DCL (NSF 20-052) that referred to the emergence of the coronavirus disease 2019 (COVID-19) and expressed NSF's interest in accepting proposals to conduct non-medical, non-clinical-care research that can be used immediately to better understand how to model and understand the spread of COVID-19; to inform and educate about the science of virus transmission and prevention; and to encourage the development of processes and actions to address this global challenge. Through this DCL, the Office of Advanced Cyberinfrastructure (OAC) within the Directorate for Computer and Information Science and Engineering is inviting RAPID proposals and supplemental funding requests to existing awards that address COVID-19 challenges through data and/or software infrastructure development activities. Such activities would be funded by the Computational and Data-Enabled Science and Engineering (CDS&E) program or the Cyberinfrastructure for Sustained Scientific Innovation (CSSI) program. Proposals in response to this DCL and the NSF DCL on COVID-19 (NSF 20-052) may also request the use of NSF-funded advanced computing resources such as Frontera, Stampede2, Bridges, Comet, and JetStream. To ensure availability of these computing resources, investigators must contact OAC prior to submission of the proposal.|
|Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus||National Institute on Drug Abuse/NIH/DHHS||Varies (NOSI Expires 3/31/2021)||Varies||NIDA is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 Novel Coronavirus (2019-nCoV, also known as COVID-19). NIDA is especially interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders. As people across the U.S. and the rest of the world prepare for what could be a pandemic of the 2019 novel coronavirus, or COVID-19, the research community should be alert to the possibility that it could affect some populations with substance use disorders or HIV particularly hard. Because it attacks the lungs, COVID-19 could be an especially serious threat to those with histories of smoking tobacco or marijuana or of vaping. People who use opioids or methamphetamine may also be vulnerable due to those drugs effects on respiratory and pulmonary health and potential effects on immune mechanisms. Likewise, those with HIV may be affected if their immune function is compromised. Additional social and environmental factors associated with drug use may worsen the transmission and treatment of COVID-19, especially among individuals who experience homelessness or incarceration, which is more common among those with a substance use disorder. Applicants should be submitted using one of the two Supplement PAs (PA-18-591, where the work proposed in the supplement is fully within the scope of the ongoing grant; and PA-18-935, for grantees wishing to expand the scope of their active grant)|
|Competitive Fund for Peace and Recovery||Innovations for Poverty Action (IPA)||See website for deadlines and how to apply||$50,000||As COVID-19 spreads around the world, IPA's Peace & Recovery Program is accepting off-cycle proposals, capped at $50,000, for time-sensitive additions to research projects that study or support the COVID-19 response. Due to the limited funding available, this funding will likely not fund entire randomized evaluations, but is meant to support research projects with additions such as:
Adding a module to an existing survey in order to track COVID-19 exposure or response,
Adding a treatment arm that may support communities' resiliency in response to COVID-19,
Anonymizing, curating, and sharing already-collected data quickly so that it can be used for decision-making by the humanitarian community, or
Downstream surveys" that follow up on a sample that participated in an already-completed randomized trial in order to identify whether the intervention studied has an impact on the communities' response to COVID-19. Interested applicants should first send an email to firstname.lastname@example.org asking for more information on how to submit an off-cycle proposal.